血液代谢标志物在原发性肝癌治疗反应及预后预测中的应用

刘志英; 周智航; 何松

doi:10.3969/j.issn.1001-5256.2023.10.028

血液代谢标志物在原发性肝癌治疗反应及预后预测中的应用

DOI: 10.3969/j.issn.1001-5256.2023.10.028

刘志英^{1, 2},
周智航¹,
何松^1, , ,

1.
重庆医科大学附属第二医院消化内科，重庆 400010
2.
西安市中心医院消化内科，西安 710000

基金项目:

重庆市自然科学基金 (2022NSCQ－MSX1038);

重庆市自然科学基金 (2022NSCQ－MSX0775)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：刘志英对文章的思路及撰写有关键贡献；周智航和何松参与修改文章关键内容。

详细信息

通信作者:
何松， hedoctor65@cqmu.edu.cn （ORCID： 0000－0002－6424－4974）

计量
- 文章访问数: 489
- HTML全文浏览量: 104
- PDF下载量: 53
- 被引次数: 0
出版历程
- 收稿日期: 2022-12-27
- 录用日期: 2023-02-21
- 出版日期: 2023-10-30

Research advances in the role of blood metabolic markers in the treatment response and prognosis prediction of primary liver cancer

Zhiying LIU^{1, 2},
Zhihang ZHOU¹,
Song HE^{1
, ,
,}

1.
Department of Gastroenterology，The Second Affiliated Hospital of Chongqing Medical University，Chongqing 400010，China
2.
Department of Gastroenterology，Xi’an Central Hospital，Xi’an 710000，China

Research funding:

Natural Science Foundation of Chongqing (2022NSCQ－MSX1038);

Natural Science Foundation of Chongqing (2022NSCQ－MSX0775)

More Information

Corresponding author: HE Song， hedoctor65@cqmu.edu.cn （ORCID： 0000－0002－6424－4974）

摘要

摘要: 原发性肝癌是全球严重的癌症负担之一。代谢重编程是癌症的一种表型，血液代谢标志物与代谢重编程密切相关，可以预测肝癌患者复发风险和生存期情况或评估肝癌治疗反应，对于分层管理患者、制订合理治疗策略以及改善患者预后具有重要意义。本文回顾了近年来关于肝癌治疗反应评估和预后预测的血液代谢组学研究，归纳了具有预测意义的血液代谢物并简述其作用机制，分析了该领域的研究现状、存在问题和发展前景。认为芳香族氨基酸、脂质、胆汁酸等代谢物对肝癌预后预测有重要的临床应用价值，且代谢组学技术在寻找有用代谢物方面具有巨大潜力，但存在技术限制、研究不足、多重影响因素等许多有待解决的问题。
- 肝肿瘤 /
- 生物标记 /
- 治疗学 /
- 预后
Abstract: Primary liver cancer is one of the most severe cancer burdens around the world. Metabolic reprogramming is one phenotype of cancer， and blood metabolic markers are closely associated with metabolic reprogramming and can predict the risk of recurrence and survival or assess the treatment response of liver cancer， with important significance in the stratified management of patients， the development of rational treatment strategies， and the improvement of patient prognosis. By reviewing the recent studies on blood metabolomics in assessing the treatment response or predicting the prognosis of liver cancer， this article summarizes the blood metabolites with predictive significance and their mechanism of action and analyzes the current research status， existing problems， and prospects of this field. It is believed that the metabolites， such as aromatic amino acids， lipids， and bile acids， have an important clinical value in predicting the prognosis of liver cancer， and metabolomics technology has great potential in finding useful metabolites， but there are still many issues to be solved， such as technical limitations， insufficient studies， and multiple influencing factors.
- Liver Neoplasms /
- Biomarkers /
- Therapeutics /
- Prognosis

HTML全文

表 1 预测肝癌治疗反应或预后的血液代谢物

Table 1. Blood metabolites for predicting treatment response or prognosis of liver cancer

治疗方式	参考文献	检测平台	代谢物	临床模型	OS	复发	主要病因
肝切除术	［17］	HPLC－MS	苯丙氨酸、胆碱	GPI评分和PMP评分	负相关		HBV
	［18］	pseudotargeted GC－MS	苯丙氨酸、半乳糖	RS_OS	负相关		HBV
	［18］	pseudotargeted GC－MS	半乳糖、酪氨酸	RS_DFS		负相关	HBV
	［19］	HPLC－MS	视黄醇、视黄醛		正相关		HBV
肝切除术/射频消融	［20］	UHPLC－QTOF－MS	1，25－二羟基胆固醇、肉豆蔻棕榈酸、12－酮基去氧胆酸、LysoPC（21∶4）和LysoPE（22∶2）		正相关		HCV
肝切除术/肝移植	［12］	HPLC－MS	DL－3－苯基乳酸、甘胆酸、L－色氨酸和1－甲基烟酰胺		负相关
肝移植	［21］	HPLC－MS	PC（16∶0/P－18∶1）、PC（18∶2/OH－16∶0）、胆酸	术前血浆列线图		正相关
射频消融、索拉非尼靶向治疗	［15］	NMR	肌醇、二甲胺		正相关		酒精
	［15］	NMR	总胆固醇、低密度脂蛋白胆固醇和低密度脂蛋白颗粒		负相关		酒精
	［16］	NMR	酪氨酸		正相关		HCV
放射治疗	［22］	GC－MS，LC－MS	脂肪酸、甘油磷脂和酰基肉碱等				酒精、HCV
放射治疗	［22］	GC－MS，LC－MS	丝氨酸、丙氨酸、牛磺酸和脂质代谢物				酒精、HCV
注：HPLC，超高效液相色谱；QTOF，四极杆飞行时间；PC，磷脂酰胆碱；LysoPE，溶血磷脂酰乙醇胺；RS，风险评分；SBRT，立体定向放射治疗；OS，总生存期；DFS，无病生存期；正/负相关，代谢物与OS/复发之间的相关性。

下载: 导出CSV

参考文献(37)

[1]	RUMGAY H, ARNOLD M, FERLAY J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77( 6): 1598－ 1606. DOI: 10.1016/j.jhep.2022.08.021.
[2]	XIA C, DONG X, LI H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J(Engl), 2022, 135( 5): 584－ 590. DOI: 10.1097/CM9.0000000000002108.
[3]	OMATA M, CHENG AL, KOKUDO N, et al. Asia－Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update[J]. Hepatol Int, 2017, 11( 4): 317－ 370. DOI: 10.1007/s12072－017－9799－9.
[4]	MEHTA N, DODGE JL, GRAB JD, et al. National experience on down－staging of hepatocellular carcinoma before liver transplant: Influence of tumor burden, alpha－fetoprotein, and wait time[J]. Hepatology, 2020, 71( 3): 943－ 954. DOI: 10.1002/hep.30879.
[5]	PAN HW, OU YH, PENG SY, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma[J]. Cancer, 2003, 98( 1): 119－ 127. DOI: 10.1002/cncr.11487.
[6]	OKUDA H, NAKANISHI T, TAKATSU K, et al. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha－fetoprotein－L3 and seronegative for des－gamma－carboxy prothrombin in comparison with those seropositive for des－gamma－carboxy prothrombin alone[J]. J Gastroenterol Hepatol, 2002, 17( 7): 772－ 778. DOI: 10.1046/j.1440－1746.2002.02806.x.
[7]	CARR BI, KANKE F, WISE M, et al. Clinical evaluation of lens culinaris agglutinin－reactive alpha－fetoprotein and des－gamma－carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States[J]. Dig Dis Sci, 2007, 52( 3): 776－ 782. DOI: 10.1007/s10620－006－9541－2.
[8]	AHN JC, TENG PC, CHEN PJ, et al. Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma[J]. Hepatology, 2021, 73( 1): 422－ 436. DOI: 10.1002/hep.31165.
[9]	CHEN VL, XU D, WICHA MS, et al. Utility of liquid biopsy analysis in detection of hepatocellular carcinoma, determination of prognosis, and disease monitoring: a systematic review[J]. Clin Gastroenterol Hepatol, 2020, 18( 13): 2879－ 2902. DOI: 10.1016/j.cgh.2020.04.019.
[10]	DU D, LIU C, QIN M, et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma[J]. Acta Pharm Sin B, 2022, 12( 2): 558－ 580. DOI: 10.1016/j.apsb.2021.09.019.
[11]	DE MATTEIS S, RAGUSA A, MARISI G, et al. Aberrant metabolism in hepatocellular carcinoma provides diagnostic and therapeutic opportunities[J]. Oxid Med Cell Longev, 2018, 2018: 7512159. DOI: 10.1155/2018/7512159.
[12]	LIU J, GENG W, SUN H, et al. Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma[J]. Gut, 2022, 71( 6): 1203－ 1213. DOI: 10.1136/gutjnl－2021－325189.
[13]	DONG TS, JACOBS JP, AGOPIAN V, et al. Duodenal microbiome and serum metabolites predict hepatocellular carcinoma in a multicenter cohort of patients with cirrhosis[J]. Dig Dis Sci, 2022, 67( 8): 3831－ 3841. DOI: 10.1007/s10620－021－07299－2.
[14]	YE G, ZHU B, YAO Z, et al. Analysis of urinary metabolic signatures of early hepatocellular carcinoma recurrence after surgical removal using gas chromatography－mass spectrometry[J]. J Proteome Res, 2012, 11( 8): 4361－ 4372. DOI: 10.1021/pr300502v.
[15]	GEYER T, RÜBENTHALER J, ALUNNI－FABBRONI M, et al. NMR－based lipid metabolite profiles to predict outcomes in patients undergoing interventional therapy for a hepatocellular carcinoma(HCC): A substudy of the SORAMIC trial[J]. Cancers(Basel), 2021, 13( 11): 2787. DOI: 10.3390/cancers13112787.
[16]	CASADEI－GARDINI A, DEL COCO L, MARISI G, et al. ¹H－NMR based serum metabolomics highlights different specific biomarkers between early and advanced hepatocellular carcinoma stages[J]. Cancers(Basel), 2020, 12( 1): 241. DOI: 10.3390/cancers12010241.
[17]	WANG Q, SU B, DONG L, et al. Liquid chromatography－mass spectrometry－based nontargeted metabolomics predicts prognosis of hepatocellular carcinoma after curative resection[J]. J Proteome Res, 2020, 19( 8): 3533－ 3541. DOI: 10.1021/acs.jproteome.0c00344.
[18]	FANG C, SU B, JIANG T, et al. Prognosis prediction of hepatocellular carcinoma after surgical resection based on serum metabolic profiling from gas chromatography－mass spectrometry[J]. Anal Bioanal Chem, 2021, 413( 12): 3153－ 3165. DOI: 10.1007/s00216－021－03281－z.
[19]	HAN J, HAN ML, XING H, et al. Tissue and serum metabolomic phenotyping for diagnosis and prognosis of hepatocellular carcinoma[J]. Int J Cancer, 2020, 146( 6): 1741－ 1753. DOI: 10.1002/ijc.32599.
[20]	NENU I, STEFANESCU H, PROCOPET B, et al. Navigating through the lipid metabolism maze: diagnosis and prognosis metabolites of hepatocellular carcinoma versus compensated cirrhosis[J]. J Clin Med, 2022, 11( 5): 1292. DOI: 10.3390/jcm11051292.
[21]	LU D, YANG F, LIN Z, et al. A prognostic fingerprint in liver transplantation for hepatocellular carcinoma based on plasma metabolomics profiling[J]. Eur J Surg Oncol, 2019, 45( 12): 2347－ 2352. DOI: 10.1016/j.ejso.2019.07.004.
[22]	NG S, JANG GH, KURLAND IJ, et al. Plasma metabolomic profiles in liver cancer patients following stereotactic body radiotherapy[J]. EBioMedicine, 2020, 59: 102973. DOI: 10.1016/j.ebiom.2020.102973.
[23]	MAZZAFERRO V, REGALIA E, DOCI R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med, 1996, 334( 11): 693－ 699. DOI: 10.1056/NEJM199603143341104.
[24]	CHENG YR, YAN D, YANG JD, et al. Effect of transcatheter arterial chemoembolization combined with sorafenib in the treatment of primary liver cancer and its impact on patients’ immune function[J]. Clin J Med Offic, 2021, 49( 3): 290－ 291. DOI: 10.16680/j.1671－3826.2021.03.16. 程瑜蓉, 严冬, 杨建东, 等. 肝动脉栓塞化疗联合索拉非尼在原发性肝癌治疗中应用效果及对患者免疫功能影响[J]. 临床军医杂志, 2021, 49( 3): 290－ 291. DOI: 10.16680/j.1671－3826.2021.03.16.
[25]	FAN J, GAO Q. Immunotherapy for hepacellular carcinoma: where there is hope, there is brightness[J]. Chin J Dig Surg, 2022, 21( 2): 199－ 204. DOI: 10.3760/cma.j.cn115610－20220215－00080. 樊嘉, 高强. 肝癌的免疫治疗: 有希望便是光明[J]. 中华消化外科杂志, 2022, 21( 2): 199－ 204. DOI: 10.3760/cma.j.cn115610－20220215－00080.
[26]	LIANG J, LI L. Progress and consideration of immunotherapy strategy for hepatocellular carcinoma[J]. Chin J Dig Surg, 2021, 20( 2): 184－ 190. DOI: 10.3760/cma.j.cn115610－20201228－00809. 梁军, 李丽. 肝癌免疫治疗策略的进展与思考[J]. 中华消化外科杂志, 2021, 20( 2): 184－ 190. DOI: 10.3760/cma.j.cn115610－20201228－00809.
[27]	HEBERER M, TALKE H, MAIER KP, et al. Metabolism of phenylalanine in liver diseases[J]. Klin Wochenschr, 1980, 58( 21): 1189－ 1196. DOI: 10.1007/BF01478875.
[28]	YANG Y, LI C, NIE X, et al. Metabonomic studies of human hepatocellular carcinoma using high－resolution magic－angle spinning ¹H NMR spectroscopy in conjunction with multivariate data analysis[J]. J Proteome Res, 2007, 6( 7): 2605－ 2614. DOI: 10.1021/pr070063h.
[29]	BIZZARRI M, DINICOLA S, BEVILACQUA A, et al. Broad Spectrum Anticancer Activity of Myo－Inositol and Inositol Hexakisphosphate[J]. Int J Endocrinol, 2016, 2016: 5616807. DOI: 10.1155/2016/5616807.
[30]	THOMAS CE, LUU HN, WANG R, et al. Association between Pre－Diagnostic Serum Bile Acids and Hepatocellular Carcinoma: The Singapore Chinese Health Study[J]. Cancers(Basel), 2021, 13( 11): 2648. DOI: 10.3390/cancers13112648.
[31]	SUN WB, LIU XL, LI W. Research advances in metabolic markers for hepatocellular carcinoma[J]. J Clin Hepatol, 2018, 34( 6): 1318－ 1324. DOI: 10.3969/j.issn.1001－5256.2018.06.040. 孙文博, 刘相良, 李薇. 肝细胞癌代谢标志物的研究进展[J]. 临床肝胆病杂志, 2018, 34( 6): 1318－ 1324. DOI: 10.3969/j.issn.1001－5256.2018.06.040.
[32]	FORMELLI F, MENEGHINI E, CAVADINI E, et al. Plasma retinol and prognosis of postmenopausal breast cancer patients[J]. Cancer Epidemiol Biomarkers Prev, 2009, 18( 1): 42－ 48. DOI: 10.1158/1055－9965.EPI－08－0496.
[33]	MONDUL AM, WATTERS JL, MÄNNISTÖ S, et al. Serum retinol and risk of prostate cancer[J]. Am J Epidemiol, 2011, 173( 7): 813－ 821. DOI: 10.1093/aje/kwq429.
[34]	LU W, SU X, KLEIN MS, et al. Metabolite measurement: pitfalls to avoid and practices to follow[J]. Annu Rev Biochem, 2017, 86: 277－ 304. DOI: 10.1146/annurev－biochem－061516－044952.
[35]	XIA H, CHEN J, SEKAR K, et al. Clinical and metabolomics analysis of hepatocellular carcinoma patients with diabetes mellitus[J]. Metabolomics, 2019, 15( 12): 156. DOI: 10.1007/s11306－019－1619－x.
[36]	CAO LL, HAN Y, WANG Y, et al. Metabolic profiling identified a novel biomarker panel for metabolic syndrome－positive hepatocellular cancer[J]. Front Endocrinol(Lausanne), 2021, 12: 816748. DOI: 10.3389/fendo.2021.816748.
[37]	ASSI N, GUNTER MJ, THOMAS DC, et al. Metabolic signature of healthy lifestyle and its relation with risk of hepatocellular carcinoma in a large European cohort[J]. Am J Clin Nutr, 2018, 108( 1): 117－ 126. DOI: 10.1093/ajcn/nqy074.